IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 11.05 SEK -0.45%
Market Cap: 572.3m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IRLAB Therapeutics AB
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Cash Taxes Paid
kr25.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Orexo AB
STO:ORX
Cash Taxes Paid
kr1.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Cash Taxes Paid
kr10.9m
CAGR 3-Years
23%
CAGR 5-Years
46%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Cash Taxes Paid
kr18.3m
CAGR 3-Years
17%
CAGR 5-Years
29%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Cash Taxes Paid
kr3.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
573.1m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
17.86 SEK
Undervaluation 38%
Intrinsic Value
Price

See Also

Back to Top